Spots Global Cancer Trial Database for TACE Combined With Sintilimab Plus Bevacizumab Biosimilar in Patients With Advanced Hepatocellular Carcinoma (TASK-02)

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: TACE Combined With Sintilimab Plus Bevacizumab Biosimilar in Patients With Advanced Hepatocellular Carcinoma (TASK-02)

Official Title: A Phase II Study of Transcatheter Arterial Chemoembolization (TACE) Combined With Sintilimab Plus Bevacizumab Biosimilar in Patients With Advanced Hepatocellular Carcinoma (TASK-02)

Study ID: NCT04954794

Conditions

Hepatocellular Carcinoma

Interventions

Sintilimab

TACE

Study Description

Brief Summary: The objective of this study is to evaluate the efficacy and safety of TACE combined with Sintilimab plus bevacizumab biosimilar in patients with advanced hepatocellular carcinoma as first-line therapy.

Detailed Description: Transarterial chemoembolization (TACE) is commonly used for the treatment of advanced hepatocellular carcinoma. Early randomized trials suggested that TACE can be accepted as the standard treatment for advanced-stage disease. However, the outcome of patients treated with TACE in real-life cohorts is still very poor. Recent studies have also supported a safe combination of immune checkpoint inhibition with TACE. And the combination of sintilimab plus bevacizumab biosimilar showed significantly improved survival in advanced HCC. Therefore, the objective of this study is to evaluate the efficacy and safety of TACE combined with anti-PD-1 antibody in patients in advanced hepatocellular carcinoma.